Akero Therapeutics, Inc. (AKRO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Akero Therapeutics provided an update on its lead NASH candidate, efruxifermin, an FGF21 analog, emphasizing its differentiated clinical profile. The company highlighted groundbreaking data from its SYMMETRY study, demonstrating a statistically significant 24% effect size in reversing cirrhosis (F4 to F3) over two years, a previously considered irreversible condition. Additionally, the HARMONY study in F2/F3 patients showed a 52% effect size in fibrosis improvement, notably exceeding the efficacy of currently approved NASH therapies like Rezdiffra and semaglutide. Akero is progressing efruxifermin through a comprehensive Phase III SYNCHRONY program, including an F4 outcomes study with strong enrollment, targeting a significant unmet medical need in advanced NASH where no approved treatments exist, despite common GI side effects and observed bone mineral density changes.

Analysis

Akero Therapeutics is strategically positioning its lead candidate, efruxifermin (EFX), as a potentially best-in-class MASH therapy, differentiated by its direct antifibrotic mechanism and compelling clinical data. The SYMMETRY study in F4 cirrhotic patients demonstrated a statistically significant 24% placebo-adjusted effect size in fibrosis regression (39% vs. 15%), a groundbreaking result for a condition long considered irreversible and in a patient group where competitors like semaglutide have shown placebo-like effects. For the less severe F2/F3 population, the HARMONY study showed an impressive 30% ITT effect size in fibrosis improvement, substantially higher than the ~11.5% for Madrigal's Rezdiffra and ~14.5% for Novo Nordisk's semaglutide. The ongoing Phase III SYNCHRONY program is comprehensive, with the F4 outcomes trial benefiting from strong enrollment and a protocol amendment to enrich for responders. While EFX's profile includes manageable GI side effects, a notable safety signal is a ~5% decrement in bone mineral density over two years, a factor being proactively managed in Phase III. The company's robust data stands out in a field where many other FGF21 analogs have failed, underscoring a significant de-risking event relative to competitors.

Key Decisions for Investors

• Investors should monitor the upcoming SYNCHRONY 'real-world' study data in the first half of 2026, which will provide the largest safety dataset to date and may offer directional efficacy signals from non-invasive markers, further de-risking the pivotal trials.
• The primary investment thesis rests on EFX's potential dominance in the F4 cirrhotic MASH market, a significant unmet need where EFX has shown unprecedented reversal data and currently approved therapies are not indicated or effective.
• Pay close attention to the bone mineral density (BMD) safety signal in future data readouts, as the market's perception of this risk and the effectiveness of mitigation strategies will be critical for EFX's long-term commercial profile.
• While the F4 opportunity is the key differentiator, the substantially higher efficacy data in F2/F3 patients positions EFX as a potential best-in-class agent across the MASH spectrum, pending confirmation in the 2027 SYNCHRONY histology trial.